The invention provides a methylene chloride solvate of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine. The invention provides a method for using such solvate.

A novel crystal form the pharmaceutical compound olanzapine, processes for its preparation and its pharmaceutical use are disclosed.

The present invention provides the novel Dihydrate D 2-methyl-thieno-benzodiazepine and a formulation therefor.

This invention relates to the use of the antipsychotic drug olanzapine for the treatment of depression, including depressive signs and symptoms and Major Depression.

Transdermal administration of olanzapine and pharmaceutically acceptable acid addition salts thereof is described. The method involves treating an individual suffering from or susceptible to psychosis, acute mania or mild anxiety states, particularly those afflicted with schizophrenia or schizophreniform illnesses, by administering olanzapine or a salt thereof through the skin or mucosal tissue, for a time period and at an administration rate effective to alleviate the symptoms of the disease. P...

The invention provides three new polymorphic forms of 2-methyl-4-[4-methyl-1-piperazinyl]-10H-thieno[2,3b][1,5]benzodiazepine (Olanzapine) (Formula A), the process for preparing the new polymorphs and pharmaceutical compositions containing the polymorphs. The new polymorphic forms of olanzapine are useful for the treatment of psychotic conditions, mild anxiety and gastrointestinal conditions. ##STR1##

Olanzapine and salts thereof are made by a process that utilizes an N-formyl olanzapine intermediate of formula (4) or a salt thereof ##STR00001##

The invention provides a method for treating a dyskinesias comprising administering an effective amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine.

The invention provides Form II, a pharmaceutically elegant, stable polymorph of olanzapine useful for treating a condition selected from the group consisting of a psychotic condition, mild anxiety and gastrointestinal conditions.

The invention provides an improved process for preparing Olanzapine as well as intermediates therefor.